Nuformix takes conservative path on cancer and IPF developments
In oncology, Nuformix has granted Oxilio a six-month option over NXP001
Company
Nuformix PLC
LON:NFX
Nuformix PLC is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
51 stories · page 3 of 3
Nuformix encouraged by pre-clinical data from IPF candidate
"Whilst this is only the pilot phase of this pre-clinical study, positive indications of anti-fibrotic activity are very encouraging."
Nuformix says there has been increased interest in its assets and their potential to treat COVID-19
“These business discussions are confidential and further announcements will be made as and when appropriate,” investors were told
Nuformix announces resignation of chief executive
The firm’s chairman, Christopher Blackwell, will lead the company as executive chairman until a successor is found
Nuformix inks development agreement; business remains resilient during lockdown
Chief executive, Dr Dan Gooding said last year’s £1.25mln fundraise and the business’ low operating costs, meant the firm was “well-placed to ride out the current worldwide issues”
Archive
PureTech Health lifted by conference news
A look at today's movers on the London Stock Exchange
Nuformix still awaiting payment from Chinese partner
Nuformix noted that its primary contact at Newsummit was dismissed in January
Archive
Proactive news snapshot: Nuformix, Polarean Imaging, Nektan, CentralNic …
A glance at some of the day's highlights from the Proactive Investors newswire
Nuformix continues to explore additional development opportunities
"We have achieved significant progress during the period, both operationally and within our lead programmes," said Dan Gooding, Nuformix's CEO
Nuformix says it has a "good shot" at doing something "really meaningful" with lung disease drug
The company represents a departure from the traditional small-cap drug development company that’s normally a binary bet on a university-discovered compound. Instead, it takes small molecule (pharmaceutical) drugs that are already on the mar
Nuformix: Repurposing small molecule drugs for patients and investors
Nuformix re-engineers a drug’s crystalline form by adding a molecule that improves it